Charl van Zyl

President and CEO, Lundbeck

Copenhagen, Denmark

About

Charl van Zyl is the President and Chief Executive Officer of Lundbeck, a Danish pharmaceutical company based in Copenhagen that researches, makes and sells medicines for brain diseases. Lundbeck's executive management page says he joined the company in September 2023 and leads its Executive Leadership Team, succeeding Deborah Dunsire in the role.

Van Zyl holds a degree in medical biochemistry from the University of Cape Town. Lundbeck's biography says he has more than 23 years of international commercial experience in pharmaceuticals. His earlier roles included Business Unit Manager at Eli Lilly, Head of Marketing and Sales at Novartis Pharma, CEO of JADO Technologies, a corporate vice president role at Bausch & Lomb, an executive vice president role at BSN Medical, and a senior role at UCB leading its neurology business. UCB is led by Jean-Christophe Tellier. Another pharmaceutical leader on Whoo is Mike Doustdar of Novo Nordisk, also a Danish company.

Whoo compiled this page from public sources: Lundbeck executive management, Wikipedia, Zonebourse. It is not affiliated with or endorsed by Charl van Zyl. Are you Charl van Zyl? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.

Want a page like this? Create yours from your résumé.

Experience

President and CEO — Lundbeck


2023 – Present

  • Leads the Executive Leadership Team
  • Executive Vice President and head of neurology — UCB

  • Senior role at UCB before moving to Lundbeck, overseeing neurology globally

Executive Vice President — BSN Medical

Corporate Vice President and Commercial Leader, EMEA — Bausch & Lomb

CEO — JADO Technologies

Head of Marketing and Sales — Novartis Pharma

Business Unit Manager — Eli Lilly and Company


Education

Degree in Medical Biochemistry — University of Cape Town


Projects